Several strategies have been explored to deliver the 14-kb, full-length dystrophin cDNA.
Models of best practice, considering the approaches of other European countries [ 5], need to be explored to elucidate how best to deliver primary care to migrant groups, whilst consideration must be given to the impact of temporary migrants on GP practice targets and resources.
Biomaterials have been extensively explored to deliver chemoattractants and create a physical microenvironment for recruited cells.
In the food industry, nanoemulsions are being explored to encapsulate, stabilize, and deliver lipophilic constituents like flavors, omega-3 fatty acids, vitamins, preservatives, nutraceuticals.
Anticancer therapeutics delivering exogenous siRNA have been explored to suppress the tumor-associated genes, but several limitations of siRNA delivery such as tumor-targeted delivery, controlled siRNA release at the sites of interest, or instabilities of siRNA in physiological fluids should be preferentially addressed for its clinical applications.
One of the approaches being explored to increase chemotherapeutic efficacy is to locally deliver chemotherapeutics encapsulated within degradable, polymeric microspheres.
To further develop this spectroscopic technique for both qualitative and quantitative analysis, technologies need to be explored in order to deliver and position nanoparticles within cells in a controllable format for a uniform distribution.
From retail websites to brick-and-mortar stores, merchants are exploring ways to deliver increasingly relevant recommendations to their customers, as a group of experts in Silicon Valley recently discussed.
Increasingly, cost-conscious providers are exploring ways to deliver tailored interventions that do not incur the same substantial costs as personal sessions.
